MT-ND1
ENSG00000198888
Target class
Enzyme
Chromosome
Mitochondrial
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MT-ND1
- Gene name
- Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1
- Gene symbol
- MT-ND1
- Previous gene symbols
- MTND1
- Protein name
- NADH-ubiquinone oxidoreductase chain 1 (EC 7.1.1.2) (NADH dehydrogenase subunit 1)
- ND1
- NAD1
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Mitochondrially encoded protein coding genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 44,249.1
- Tissue specificity (Gini)
- 0.296
- Tissue specificity (tau)
- 0.512
- KEGG gene identifiers
- hsa:4535
- Protein interaction confidence
- 0.934981
- Protein interaction partners
- 108
- R-HSA-5419276
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 4262
- Start position
- 3307
- Chromosome
- Mitochondrial
- Strand
- Forward
- Mitochondrion inner membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.511921
- Expression inequality (Gini)
- 0.295878
Expression in transcripts per million
- Brain - Cortex
- 44,249.1
- Brain - Substantia nigra
- 42,117.3
- Brain - Putamen (basal ganglia)
- 40,902.9
- Brain - Amygdala
- 39,954.5
- Brain - Hippocampus
- 39,582.1
Expression in transcripts per million
- Brain - Cortex44,249.1
- Brain - Substantia nigra42,117.3
- Brain - Putamen (basal ganglia)40,902.9
- Brain - Amygdala39,954.5
- Brain - Hippocampus39,582.1
- Heart - Left Ventricle39,102.2
- Brain - Caudate (basal ganglia)38,308.1
- Brain - Anterior cingulate cortex (BA24)38,019.8
- Brain - Nucleus accumbens (basal ganglia)35,612.3
- Brain - Hypothalamus34,501.3
- Heart - Atrial Appendage33,727.8
- Kidney - Cortex33,272.7
- Brain - Frontal Cortex (BA9)33,268.4
- Kidney - Medulla32,532.4
- Muscle - Skeletal31,413.1
- Brain - Spinal cord (cervical c-1)31,192.7
- Brain - Cerebellum30,607
- Adipose - Subcutaneous28,162.9
- Adrenal Gland26,468.8
- Breast - Mammary Tissue24,759.3
- Stomach24,540.9
- Adipose - Visceral (Omentum)24,195.2
- Testis23,425.2
- Brain - Cerebellar Hemisphere23,043
- Colon - Transverse22,510
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0031966
- GO:0045271
- GO:0005515
- GO:0008137
Parkinsonian motor deficits
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Evidence source
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor